Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda , sending its ...

Novavax ( ($NVAX) ) has risen by 24.00%. Read on to learn why. Novavax has experienced a notable 24.00% increase in its stock price over the past ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Novavax, with a price target of $8.00. The company’s shares closed yesterday at $7.58. Take advantage of TipRanks ...

Novavax (NASDAQ:NVAX), known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profita ...

Novavax on Wednesday said that the postmarketing commitment study is anticipated to occur during 2025 and 2026 and cost ...

Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's ...

Novavax’s COVID-19 vaccine has faced a rocky road to authorization in the United States. It was initially part of Operation Warp Speed in early 2020, the first wave of US government funding ...